Vaccine Research and Adjuvant Discovery
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".
Deadline for manuscript submissions: 25 July 2024 | Viewed by 264
Special Issue Editor
Special Issue Information
Dear Colleagues,
The insidious threat posed by emerging infectious diseases requires the development of novel and highly effective vaccine strategies that provide both immediate short-term and durable long-term antigen-specific immunity. Especially vulnerable to these threats are high-risk populations, such as the elderly, newborns, and immune-compromised individuals. Many new vaccines include the use of synthetic and recombinant subunit antigens to improve manufacturability and safety but unfortunately often result in decreased vaccine potency and long-term efficacy. In addition, conventional vaccines need to be administered multiple times, can take a long time to build up protective antibodies, and often provide weak and/or waning protection in infants and the elderly. One way to circumvent these issues is the use of next-generation adjuvants. However, despite many decades of development, only a few adjuvants are currently licensed for use in vaccines. Moreover, the majority of existing vaccines contain a single adjuvant, and recent evidence suggests that this is unlikely to be sufficient for the induction of a protective immune response against many emerging infectious diseases. The future of vaccines, as arguably the most impactful medical achievement of our time, potentially rests on the discovery and development of new technologies. This is particularly critical for new pathogens and those maladies that are the most difficult to treat using conventional vaccine strategies. The success of RNA vaccines for COVID-19 and adjuvanted vaccines for shingles highlight the future and the breadth of work still to be carried out. This Special Issue will attempt to highlight efforts toward new vaccine and adjuvant technologies.
Dr. Kendal Ryter
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- C-type lectin receptor
- mincle
- toll-like receptor
